glp-1 layoffs news Your Weight-Loss Drugs Are Next on the Corporate Chopping Block Lilly is now pharma's top

A detailed 2025 case report using deep brain stimulation monitoring in a patient with severe obesity and binge eating disorder found that GLP-1s suppressive effect on food-related brain activity was present during treatment but diminished over time, with one specific effect on the nucleus accumbens wearing off after approximately five months despite continued treatment suggesting the brain may partially adapt to the medications effect on reward circuitry even while still taking it

Lipid Peroxidation in Neurodegeneration

Sordo L, Du A, Sandadi V et al (2025) Leptin levels are associated with body mass index and Alzheimers disease in Down syndrome

Liver Non-alcoholic fatty liver disease (NAFLD) describes a disorder with excessive deposition of fat within the liver with increasing prevalence in parallel to obesity and diabetes, which are major risk factors for NAFLD (143)

These products are not drugs, foods, or cosmetics

What is the status of platelet derived preparations (e.g PRP and PRF)